Home / Available CME / Changing ARV Therapy
Back to Top
6:00 PM - 6:30 PM Check-in/Walk-in Registration
Credit Designation Statement
Changing ARV Therapy in Patients with an Undetectable Viral Load: A Debate
|
Jointly Sponsored by:
|
|
|
About the Program
- Program Overview
- Learning Objectives
- Intended Audience
- Course Director
- Faculty
- Schedule Dates and Locations
- Accreditation Statement
- Credit Designation Statement
- Disclosure of Conflicts of Interest
Program Overview
Recent updates to international treatment guidelines (DHHS, IAS-USA, and EACS) contain sections pertinent specifically to the reasons for switching ARV regimens in potentially virologically suppressed patients. Many patients could benefit from changes to more convenient regimens with potentially better safety and tolerability profiles. This program will provide the information needed to adequately assess those patients in whom treatment could be enhanced when considering measures beyond viral load.
Back to Top
Learning Objectives
Upon completion of the program, participants should be able to:
-
Assess the risks and potential benefits of changing ARV therapy in a patient with an HIV RNA <50 copies/mL;
-
Discuss the differences between various ARV agents and regimens regarding adverse events, including short- and long-term tolerability issues, morphologic and metabolic disturbances, and cardiovascular risk;
-
Describe clinical strategies to minimize ARV risks while maximizing the chance for long-term virologic suppression;
-
Integrate best practice information and data through interactions with leading clinicians.
Back to Top
Intended Audience
This activity is intended for physicians, physicians' assistants, advanced practice nurses, and other health care professionals actively involved in the treatment and management of patients with HIV-infection. It is tuition-free and there are no prerequisites.
Back to Top
Course Director
Calvin J. Cohen, MD, MS
Research Director, CRI New England
Clinical Instructor, Harvard Medical School
Boston, Massachusetts
Back to Top
Faculty
| David Fletcher, MD General Internal Medicine/HIV/Hepatitis Maple Leaf Medical Clinic Toronto, Ontario |
John Gill, MD |
|
Mark Tyndall, MD |
Sharon L Walmsley, MD Professor of Medicine, University of Toronto Director of Clinical Research, Immunodeficiency Clinic, Toronto Hospital Toronto, Ontario |
Schedule Date and Location
To Register Click on Location or call (856) 506-5790
| London, Ontario | Wednesday June, 8, 2011 |
Schedule for all programs:
6:00 PM - 6:30 PM Check-in/Walk-in Registration
6:30 PM - 8:30 PM Discussion
8:30 PM Adjourn
Back to Top
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and ViralEd, LLC. PIM is accredited by the ACCME to provide continuing medical education for physicians.
Back to Top
Credit Designation Statement
Postgraduate Institute for Medicine designates this educational activity for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Back to Top
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Supported by an unrestricted educational grant by Gilead Sciences Canada, Inc.
Share this page:
